Research
Hormonal
Neurokinin 2 receptor (NK2R) activation reduces appetite and body weight in mice without the gastrointestinal side effects associated with GLP-1 based treatments.
Research is exploring new drugs that target Neurokinin 2 Receptors (NK2R) to suppress appetite without causing the nausea common with current GLP-1 drugs. These are currently only proven effective in mice, so they are not yet available for human use.
LimitedSupportsLOW confidence
novel candidate anti-obesity drugs have been shown to activate neurokinin 2 receptors (NK2Rs) in mice, leading to appetite suppression without the side effects observed with previous generations of treatments.
Why this rating
Based on preclinical mouse studies; human clinical trial data is explicitly stated as necessary.
Source
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Saqer S. Alotaibi et al. · Experimental and Therapeutic Medicine · 2025
DOI 10.3892/etm.2025.12912
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →